---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/40742960.md"
description: "$Novo Nordisk AS(NVO.US) Just look at the key information. 1. The Parkinson's therapy was acquired. 2. The stock grant. These two pieces of information seem unrelated and insignificant. Let's talk about the first one: Would a normal and healthy company rely on being acquired to make its books look good? The second one: Granting stock to test market reaction? And a grant doesn't even count as a reduction in holdings?"
datetime: "2026-05-13T16:35:47.000Z"
locales:
  - [en](https://longbridge.com/en/topics/40742960.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/40742960.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/40742960.md)
author: "[人民资本](https://longbridge.com/en/profiles/19004565.md)"
---

# $Novo Nordisk AS(NVO.US) Just look at the key info…


### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

## Comments (2)

- **满仓nvo等暴涨 · 2026-05-13T18:08:32.000Z**: Two points are completely useless. Parkinson's disease is clearly not NVO's main business and has nothing to do with its core GLP-1 business. Secondly, how can a gift of 50 shares be considered news?
  - **人民资本** (2026-05-13T23:39:34.000Z): You're right